Citations (1)
Keep up to date with the latest research on this topic with citation updates for this article.
Journal of Medical Economics
Volume 25, 2022 - Issue 1
Hematology
Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe
Maria Elisa Mancusoa Centre for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Italy
https://orcid.org/0000-0002-7113-4028
https://orcid.org/0000-0002-7113-4028, Giancarlo Castamanb Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Center for Bleeding Disorders, Florence, ItalyCorrespondence[email protected]
https://orcid.org/0000-0003-4973-1317
https://orcid.org/0000-0003-4973-1317, , , Aleksandra Drzewieckac Creativ-Ceutical, Krakow, Polandhttps://orcid.org/0000-0003-3396-8571
https://orcid.org/0000-0003-3396-8571, Zalmai Hakimie Swedish Orphan Biovitrum Ltd, Stockholm, Swedenhttps://orcid.org/0000-0001-5835-8599
https://orcid.org/0000-0001-5835-8599, & Francis Fatoyef Faculty of Health and Education, Manchester Metropolitan University, Manchester, UKhttps://orcid.org/0000-0002-3502-3953
https://orcid.org/0000-0002-3502-3953 show all